Stay updated on ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial

Sign up to get notified when there's something new on the ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The clinical trial record for the Abraxane and pembrolizumab study in advanced urothelial cancer is now displayed, including study design, participation criteria, outcome measures, and study documents. The previous 403 error page is gone.
    Difference
    49%
    Check dated 2026-11-08T15:04:21.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T16:13:42.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    A notice about NIH’s terminology transition appears above the ClinicalTrials.gov page, which still shows a 403 Forbidden error instead of the study record.
    Difference
    1%
    Check dated 2026-10-25T15:27:51.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T21:00:27.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The footer’s site revision label changes from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-11T21:52:53.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    A new Revision: v3.7.0 is added to the page. A large set of study documents and related items, including Informed Consent Form entries and the Study Protocol/SAP, were removed from the Study Documents section.
    Difference
    18%
    Check dated 2026-09-20T19:25:39.000Z thumbnail image

Stay in the know with updates to ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial page.